Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cardinal Health (CAH)

Cardinal Health raises FY2026 EPS outlook to $9.30-$9.50 as Q4 revenue is flat

Positive Impact 4 of 5 earnings Written later

Cardinal Health reported fourth-quarter and fiscal 2025 results and raised its fiscal 2026 non-GAAP diluted EPS outlook to $9.30 to $9.50, a $0.20 increase from the preliminary range given at its June 2025 Investor Day. Fourth-quarter revenue was flat at $60.2 billion, while non-GAAP diluted EPS rose 13% to $2.08, and the company said results were helped by segment profit growth. The company also announced that its Specialty Alliance unit has agreed to acquire Solaris Health, a urology management services organization.

Key points

  • Q4 FY2025 revenue was $60.2 billion, flat year over year; non-GAAP diluted EPS rose 13% to $2.08
  • Fiscal 2025 GAAP diluted EPS was $6.45; non-GAAP diluted EPS rose 9% to $8.24
  • FY2026 non-GAAP EPS outlook raised to $9.30 to $9.50, from $9.10 to $9.30 previously
  • Definitive agreement to acquire Solaris Health, announced in a separate news release on August 12, 2025

The filing

CompanyCardinal Health (CAH)
Form8-K, current report
Filed with the SECAug 12, 2025, 6:59 AM ET
Accession number0000721371-25-000075

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.